IO Biotech (NASDAQ:IOBT - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect IO Biotech to post earnings of ($0.45) per share for the quarter.
IO Biotech Price Performance
IOBT traded up $0.01 on Friday, hitting $1.00. The company had a trading volume of 67,413 shares, compared to its average volume of 273,015. IO Biotech has a 52-week low of $0.66 and a 52-week high of $1.73. The stock has a fifty day simple moving average of $0.95 and a 200-day simple moving average of $0.94. The firm has a market capitalization of $65.88 million, a P/E ratio of -0.73 and a beta of 0.09.
Analysts Set New Price Targets
Several research firms have weighed in on IOBT. HC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of IO Biotech in a research note on Tuesday, April 1st. Piper Sandler upgraded IO Biotech to a "strong-buy" rating in a research note on Wednesday, March 12th.
Get Our Latest Stock Report on IOBT
About IO Biotech
(
Get Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
See Also
Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
